203 related articles for article (PubMed ID: 16716799)
1. Optimizing gemcitabine regimens in ovarian cancer.
Pecorelli S; Pasinetti B; Tisi G; Odicino F
Semin Oncol; 2006 Apr; 33(2 Suppl 6):S17-25. PubMed ID: 16716799
[TBL] [Abstract][Full Text] [Related]
2. Management of platinum-sensitive recurrent ovarian cancer.
Pfisterer J; Ledermann JA
Semin Oncol; 2006 Apr; 33(2 Suppl 6):S12-6. PubMed ID: 16716798
[TBL] [Abstract][Full Text] [Related]
3. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
Edwards SJ; Barton S; Thurgar E; Trevor N
Health Technol Assess; 2015 Jan; 19(7):1-480. PubMed ID: 25626481
[TBL] [Abstract][Full Text] [Related]
4. Future directions in the chemotherapy of ovarian cancer.
Ozols RF
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-86-S15-90. PubMed ID: 9346230
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine plus carboplatin in platinum-sensitive recurrent ovarian carcinoma.
Kose MF; Meydanli MM; Tulunay G
Expert Rev Anticancer Ther; 2006 Mar; 6(3):437-43. PubMed ID: 16503860
[TBL] [Abstract][Full Text] [Related]
6. The role of gemcitabine in first-line treatment of advanced ovarian carcinoma.
Thigpen T
Semin Oncol; 2006 Apr; 33(2 Suppl 6):S26-32. PubMed ID: 16716800
[TBL] [Abstract][Full Text] [Related]
7. The role of gemcitabine-based doublets in the management of ovarian carcinoma.
Thigpen T
Semin Oncol; 2002 Feb; 29(1 Suppl 1):11-6. PubMed ID: 11840415
[TBL] [Abstract][Full Text] [Related]
8. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
9. Dose finding study for combination treatment with topotecan and gemcitabine of patients with recurrent ovarian cancer after failure of first-line chemotherapy with Paclitaxel and platinum.
Sehouli J; Stengel D; Oskay G; Blohmer J; Kaubitzsch S; Lichtenegger W;
Onkologie; 2004 Feb; 27(1):58-64. PubMed ID: 15007250
[TBL] [Abstract][Full Text] [Related]
10. Treatment outcomes of paclitaxel for refractory or recurrent epithelial ovarian cancer patients in Thailand.
Pitakkarnkul S; Tangjitgamol S; Srijaipracharoen S; Manusirivithaya S; Pataradool K; Prutthiphongsit W; Khunnarong J; Thavaramara T
Asian Pac J Cancer Prev; 2013; 14(4):2421-7. PubMed ID: 23725151
[TBL] [Abstract][Full Text] [Related]
11. Role of gemcitabine in ovarian cancer treatment.
Lorusso D; Di Stefano A; Fanfani F; Scambia G
Ann Oncol; 2006 May; 17 Suppl 5():v188-94. PubMed ID: 16807454
[TBL] [Abstract][Full Text] [Related]
12. Developmental chemotherapy in advanced ovarian cancer: incorporation of newer cytotoxic agents in a phase III randomized trial of the Gynecologic Oncology Group (GOG-0182).
Bookman MA
Semin Oncol; 2002 Feb; 29(1 Suppl 1):20-31. PubMed ID: 11840417
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy.
Sehouli J; Stengel D; Oskay G; Camara O; Hindenburg HJ; Klare P; Blohmer J; Heinrich G; Elling D; Ledwon P; Lichtenegger W;
Ann Oncol; 2002 Nov; 13(11):1749-55. PubMed ID: 12419747
[TBL] [Abstract][Full Text] [Related]
14. Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR).
Sehouli J; Chekerov R; Reinthaller A; Richter R; Gonzalez-Martin A; Harter P; Woopen H; Petru E; Hanker LC; Keil E; Wimberger P; Klare P; Kurzeder C; Hilpert F; Belau AK; Zeimet A; Bover-Barcelo I; Canzler U; Mahner S; Meier W
Ann Oncol; 2016 Dec; 27(12):2236-2241. PubMed ID: 27789470
[TBL] [Abstract][Full Text] [Related]
15. Treatment of recurrent platinum resistant ovarian or peritoneal cancer with gemcitabine and doxorubicin: A phase I/II trial of the Puget Sound Oncology Consortium (PSOC 1602).
Goff BA; Thompson T; Greer BE; Jacobs A; Storer B;
Am J Obstet Gynecol; 2003 Jun; 188(6):1556-62; discussion 1562-4. PubMed ID: 12824993
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine, platinum, and paclitaxel regimens in patients with advanced ovarian carcinoma.
Hansen SW
Semin Oncol; 2002 Feb; 29(1 Suppl 1):17-9. PubMed ID: 11840416
[TBL] [Abstract][Full Text] [Related]
17. Gemcitabine in patients with ovarian cancer.
Poveda A
Cancer Treat Rev; 2005; 31 Suppl 4():S29-37. PubMed ID: 16360545
[TBL] [Abstract][Full Text] [Related]
18. Systemic therapy for ovarian cancer: current status and new treatments.
Ozols RF
Semin Oncol; 2006 Apr; 33(2 Suppl 6):S3-11. PubMed ID: 16716797
[TBL] [Abstract][Full Text] [Related]
19. A phase II randomized controlled study of pegylated liposomal doxorubicin and carboplatin vs. gemcitabine and carboplatin for platinum-sensitive recurrent ovarian cancer (GOTIC003/intergroup study).
Fujiwara H; Ushijima K; Nagao S; Takei Y; Shimada M; Takano M; Yoshino K; Kawano Y; Hirashima Y; Nagase S; Nishio S; Nishikawa T; Ito K; Shoji T; Kimura E; Takano T; Sugiyama T; Kigawa J; Fujiwara K; Suzuki M
Int J Clin Oncol; 2019 Oct; 24(10):1284-1291. PubMed ID: 31127479
[TBL] [Abstract][Full Text] [Related]
20. Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182-ICON5.
Copeland LJ; Bookman M; Trimble E;
Gynecol Oncol; 2003 Aug; 90(2 Pt 2):S1-7. PubMed ID: 12927999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]